Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fortrea Holdings Inc.FTRE · Entity 4623 | Director | June 10, 2026 | June 12, 2026 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fortrea Holdings Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,453 |
Reported balance
After 2026-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-10 · Exercise / conversion · Acquired 38,817 · Balance 52,453 F1: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F2: This number reflects the aggregate amount of Common Stock held by the reporting person. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Exercise / conversion · Disposed 38,817 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F3: Represents an RSU award that vested in its entirety on June 10, 2026. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 12,852 |
Reported balance
After 2026-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-10 · Grant · Acquired 12,852 · Balance 12,852 F4: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). F5: Represents a RSU award that vests in its entirety twelve months after June 10, 2026, subject to the Reporting Person's continued service as a director. F6: This number reflects the aggregate number of RSUs held by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date.
F2: This number reflects the aggregate amount of Common Stock held by the reporting person.
F3: Represents an RSU award that vested in its entirety on June 10, 2026.
F4: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock").
F5: Represents a RSU award that vests in its entirety twelve months after June 10, 2026, subject to the Reporting Person's continued service as a director.
F6: This number reflects the aggregate number of RSUs held by the reporting person.
Ultragenyx Pharmaceutical Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,116 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 7,751 · Balance 31,116 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.80 · Expires 2036-05-14 | Direct | 14,058 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Grant · Acquired 14,058 · Balance 14,058 F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 16:09 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 12,852 | $0.00 | $0.00 |
DisclosureSEC source: 0001965040-26-000081 · form4.xml · derivative · entry 3 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,852 Underlying: Common Stock · 12,852 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). F5 · derivative.exercise_date: Represents a RSU award that vests in its entirety twelve months after June 10, 2026, subject to the Reporting Person's continued service as a director. F5 · derivative.expiration_date: Represents a RSU award that vests in its entirety twelve months after June 10, 2026, subject to the Reporting Person's continued service as a director. F6 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 16:09 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionRestricted Stock Unit · Derivative | 38,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001965040-26-000081 · form4.xml · derivative · entry 2 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F3 · derivative.exercise_date: Represents an RSU award that vested in its entirety on June 10, 2026. F3 · derivative.expiration_date: Represents an RSU award that vested in its entirety on June 10, 2026. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 16:09 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionCommon Stock | 38,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001965040-26-000081 · form4.xml · nonDerivative · entry 1 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F2 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| May 14, 2026 Filed May 18, 2026 18:39 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 14,058 | $0.00 Strike: $25.80 | $0.00 |
DisclosureSEC source: 0001924797-26-000002 · ownership.xml · derivative · entry 2 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,058 Underlying: Common Stock · 14,058 shares Expires 2036-05-14 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. Read SEC document |
| May 14, 2026 Filed May 18, 2026 18:39 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 7,751 | $0.00 | $0.00 |
DisclosureSEC source: 0001924797-26-000002 · ownership.xml · nonDerivative · entry 1 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,116 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:15 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 38,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-017401 · form4.xml · derivative · entry 1 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,817 Underlying: Common Stock · 38,817 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. Common Stock. F2 · derivative.exercise_date: Represents a RSU award that vests in its entirety twelve months after June 10, 2025, subject to the Reporting Person's continued service as a director. F2 · derivative.expiration_date: Represents a RSU award that vests in its entirety twelve months after June 10, 2025, subject to the Reporting Person's continued service as a director. F3 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| May 15, 2025 Filed May 19, 2025 18:31 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 10,787 | $0.00 Strike: $34.84 | $0.00 |
DisclosureSEC source: 0000950170-25-074661 · ownership.xml · derivative · entry 2 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,787 Underlying: Common Stock · 10,787 shares Expires 2035-05-15 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026. Read SEC document |
| May 15, 2025 Filed May 19, 2025 18:31 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,740 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074661 · ownership.xml · nonDerivative · entry 1 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,365 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026. Read SEC document |
| May 14, 2025 Filed May 16, 2025 16:47 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionRestricted Stock Unit · Derivative | 7,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014739 · form4.xml · derivative · entry 2 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F3 · derivative.exercise_date: Represents an RSU award that vested in its entirety on May 14, 2025. F3 · derivative.expiration_date: Represents an RSU award that vested in its entirety on May 14, 2025. Read SEC document |
| May 14, 2025 Filed May 16, 2025 16:47 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionCommon Stock | 7,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014739 · form4.xml · nonDerivative · entry 1 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F2 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| July 18, 2024 Filed Jul 19, 2024 17:21 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionRestricted Stock Unit · Derivative | 6,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-020748 · form4.xml · derivative · entry 2 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,282 Underlying: Common Stock · 6,354 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. F3 · derivative.exercise_date: The RSUs vested on July 18, 2024. F3 · derivative.expiration_date: The RSUs vested on July 18, 2024. F4 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| July 18, 2024 Filed Jul 19, 2024 17:21 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionCommon Stock | 6,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-020748 · form4.xml · nonDerivative · entry 1 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. F2 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 14:23 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 9,900 | $0.00 Strike: $37.42 | $0.00 |
DisclosureSEC source: 0000950170-24-075486 · ownership.xml · derivative · entry 2 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,900 Underlying: Common Stock · 9,900 shares Expires 2034-06-18 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 14:23 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,345 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-075486 · ownership.xml · nonDerivative · entry 1 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,625 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025. Read SEC document |
| May 14, 2024 Filed May 16, 2024 16:37 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 7,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-015694 · form4.xml · derivative · entry 1 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,636 Underlying: Common Stock · 7,282 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. F2 · derivative.exercise_date: Represents a RSU award that vests in its entirety twelve months after May 14, 2024, subject to the Reporting Person's continued service as a director. F2 · derivative.expiration_date: Represents a RSU award that vests in its entirety twelve months after May 14, 2024, subject to the Reporting Person's continued service as a director. F3 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 17:08 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 6,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-021034 · form4.xml · derivative · entry 1 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,354 Underlying: Common Stock · 6,354 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. F2 · derivative.exercise_date: The RSUs vest in full on July 18, 2024, subject to the Reporting Person's continued service as a director. F2 · derivative.expiration_date: The RSUs vest in full on July 18, 2024, subject to the Reporting Person's continued service as a director. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 14:33 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 7,110 | $0.00 Strike: $51.82 | $0.00 |
DisclosureSEC source: 0001209191-23-035692 · doc4.xml · derivative · entry 2 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,110 Underlying: Common Stock · 7,110 shares Expires 2033-06-07 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 14:33 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035692 · doc4.xml · nonDerivative · entry 1 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,280 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 13:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 6,245 | $0.00 Strike: $60.57 | $0.00 |
DisclosureSEC source: 0001209191-22-039564 · doc4.xml · derivative · entry 2 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,245 Underlying: Common Stock · 6,245 shares Expires 2032-06-24 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 13:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039564 · doc4.xml · nonDerivative · entry 1 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,420 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. Read SEC document |
| April 19, 2022 Filed Apr 22, 2022 12:31 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 9,525 | $0.00 Strike: $78.10 | $0.00 |
DisclosureSEC source: 0001209191-22-025279 · doc4.xml · derivative · entry 2 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,525 Underlying: Common Stock · 9,525 shares Expires 2032-04-19 F3 · derivative.exercise_date: The option shall vest with respect to 1/36th of the shares monthly such that the option shall be fully vested on the third anniversary of the grant date. Read SEC document |
| April 19, 2022 Filed Apr 22, 2022 12:31 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-025279 · doc4.xml · nonDerivative · entry 1 Ray Amrit · CIK 0001924797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,120 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/3rd of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the third anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.